Surv BioPharma key facts
as of Oct 2026- Developer of gene therapies designed to improve the treatment of various diseases.
- Surv BioPharma is valued at approximately $32.5M as of Oct 2026 (last reported valuation).
- It has raised $21.3M; the latest was Early Stage VC ($13.9M) in Dec 2025.
- Notable investors include Nippon Venture Capital, FFG Venture Business Partners, Keio Innovation Initiative, Kyoto University Innovation Capital, Sagin Capital & Consulting — 15 tracked in total.
- Status: Privately Held (backing).
Surv BioPharma's last reported valuation, Dec 2025. Nothing priced has surfaced since.
- ·The complete investor list: 15 names
- ·Watch Surv BioPharma: the Monday email on marks, rounds and moves
Surv BioPharma funding rounds
No funding rounds for Surv BioPharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Surv BioPharma
15+Surv BioPharma valuation
Surv BioPharma's last reported valuation was $32.5 million in Dec 2025. No priced round, secondary trade or fund mark has surfaced since.
Surv BioPharma investors
15 investors are on record for Surv BioPharma, including Nippon Venture Capital, FFG Venture Business Partners, Keio Innovation Initiative and Kyoto University Innovation Capital.
About Surv BioPharma
Developer of gene therapies designed to improve the treatment of various diseases. The company's platform utilizes drug delivery systems and targeted therapy approaches, aiming to enhance drug efficacy while minimizing side effects, enabling healthcare providers to offer more precise and effective treatments to patients in need of specialized medical care.
- Sector
- Healthcare
- HQ
- Kagoshima, Japan
- Founded
- 2022
- Employees
- 12
- Website
- survbiopharma.co.jp/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.